-
Post-Surgery
Peptides For Post-Surgery Healing
Are there any studies regarding post surgery use of peptides? Let us break this down below… Read more -
Market
Big Pharma And The View On Peptides
You may wonder why your Doctor doesn’t prescribe you peptides, that is a great question that needs to be put… -
MCAS
MCAS and Peptides: A Practical Guide
Mast cells are part of your immune system. They’re meant to help with threats (like allergens or infections) by releasing…
-
Vesugen
3AA Limited HumanIn Plain English: Vesugen is a three-amino-acid chain — lysine, glutamic acid, and aspartic acid — modelled on a peptide sequence found in vascular wall proteins. Small Russian clinical studies report improvements in arterial blood flow, reductions in erectile dysfunction linked to atherosclerosis, and benefits in lower-limb arterial insufficiency in elderly patients. In cell and mouse experiments, it restores the Ki-67 proliferation marker in aged endothelial cells, normalises gap-junction proteins (connexins), upregulates SIRT1, and — at a separate neurological level — recovers mushroom-spine density in an Alzheimer's mouse model. Western replication is absent; all human clinical data originates from a single Russian research group.
2D StructureQuick Facts€3.5 Avg / mgFocusCardiovascular Support Healthy Aging +1RouteSubQEvidenceLimited Human ~15-20 peer-reviewed papers (2012-2021); 2 small human trials (n=41 each); no independent replicationFlagsNo Independent Western Replication No Published Pharmacokinetic Data Cell Proliferation Stimulation Prooxidant Activity Reported (in vitro) Small Human Trial Sizes Contraindicated in Pregnancy / Breastfeeding Generally Well Tolerated in Short CoursesSignalsMatrix soonNo community data yetAppears automatically once votes arrive.− -
Vesilut
2AA PreclinicalIn Plain English: Vesilut is a two-amino-acid chain — glutamic acid followed by aspartic acid (Glu-Asp, single-letter code ED) — synthesised by directed analysis of urinary bladder tissue at the St. Petersburg Institute of Bioregulation and Gerontology. The dipeptide belongs to the same family as Cardiogen (heart), Bronchogen (lung), Prostamax (prostate), and Pancragen (pancreas); each sequence was designed to home to a specific organ based on compositional enrichment at gene-promoter sites in the target tissue. In the Khavinson classification Vesilut is the 'Cytogen' (synthetic form) corresponding to the natural polypeptide extract marketed as Vezusten or Vesusten. At just 262 Da it is small enough to diffuse through cell membranes, enter the nucleus, and interact directly with chromatin without requiring a surface receptor. The net effect proposed is decondensation of age-compressed heterochromatin, reactivation of silenced genes governing urothelial integrity, smooth muscle tone, and mucosal immune defence, and reduction of inflammatory mediators. In rat studies with induced bladder irritation, treated groups showed approximately 40% less tissue damage and faster mucosal healing. A 2024 prospective cohort study (n=20 women with idiopathic overactive bladder, Kovalev et al.) documented statistically significant reductions in daily urination frequency, nocturia, and urge incontinence episodes, with maximum cystometric capacity increasing from 267 to 320 ml. A 2024 PubMed-indexed Russian review (Kuzmin, PMID 39563546) and a 2025 ICS-EUS conference abstract (Galkina and Galkin, n=48) support the same bladder-specific peptide complex under the Vezusten brand. Direct Vesilut-specific PubMed-indexed publications remain sparse; most mechanistic evidence is drawn from the broader Khavinson dipeptide class. Sold as the original Russian capsule (Peptide Bio / Firma-Vita, 60 × 0.275 g) and as lyophilised research powder globally.
2D StructureQuick Facts€3.0 Avg / mgFocusCardiovascular Support Healthy Aging +1RouteOralEvidencePreclinical ~2–3 papers naming Vesilut (Glu-Asp); +2 clinical on related Vezusten complex; no independent replicationFlagsMinimal Human Clinical Data No Pharmacokinetic Characterisation Single-Institute Research Base No Drug Interaction Data Contraindicated Populations (standard bioregulator exclusions) No Serious Adverse Events ReportedSignalsMatrix soonNo community data yetAppears automatically once votes arrive.− -
Vialox (Pentpeptide-3V)
5AA Limited HumanIn Plain English: This is a small man‑made protein fragment designed to act on tiny muscles under the skin. It sends signals that may help those muscles relax a bit so expression lines and wrinkles can look softer on the surface.
2D StructureQuick Facts– Avg / mgFocusAesthetic Dermatology Cosmetic Anti-Aging +1RouteTopicalEvidenceLimited Human <10 PubMed-indexed results for Pentapeptide-3/Vialox; key efficacy ref Gorouhi & Maibach 2009; no independent RCTFlagsCosmetic Ingredient Only Limited Independent Clinical DataSignalsMatrix soonNo community data yetAppears automatically once votes arrive.− -
VIP
28AA Clinical (Niche Indication)In Plain English: VIP is a signalling peptide your nervous system naturally produces to calm inflammation, relax airways and blood vessels, and regulate immune responses. Scientists have studied it for over 50 years. In clinical practice it is best known as the capstone of the Shoemaker protocol for mould illness (CIRS)—where intranasal VIP is used to normalise brain volume loss and inflammatory markers after the upstream steps are complete. It is also being studied as inhaled aviptadil for pulmonary arterial hypertension, where it was granted FDA Orphan Drug and Breakthrough Therapy designations.
2D StructureQuick Facts€9.0 Avg / mgFocusImmune Modulation Neuroprotection +1RouteInhaled IV Nasal SubQEvidenceClinical (Niche Indication) 15,084 publications on PubMed as of May 2026 (search: "vasoactive intestinal peptide")FlagsHypotension Risk Compounded RX Only (USA) Research Chemical (Non-RX markets) VIPoma Contraindication Pregnancy & Breastfeeding Transient Flushing / TachycardiaSignalsMatrix soonNo community data yetAppears automatically once votes arrive.− -
Triptorelin
10AA Approved DrugIn Plain English: Triptorelin is a ten-amino-acid synthetic analogue of your body's gonadotropin-releasing hormone, with one strategic swap: D-tryptophan replaces glycine at position 6. That single change makes it 100× harder for enzymes to break down and 100× better at gripping the GnRH receptor. The result is paradoxical — it first triggers a massive surge of LH and FSH (the 'flare'), then over 2–4 weeks it overwhelms the pituitary so completely that hormone production collapses to castrate levels. Monthly depot injections then keep it there. Used medically for over 25 years to block hormones driving prostate tumours, endometriosis pain, and premature puberty.
2D StructureQuick Facts€18.0 Avg / mgFocusHormone Modulation Oncology +1RouteIM SubQEvidenceApproved Drug 2,458 results on PubMed for 'triptorelin' (verified 2026-05-04)FlagsTestosterone Flare (Tumour Flare Risk) Bone Mineral Density Loss Cardiovascular Risk (FDA Boxed Warning) Hot Flashes (50–75% incidence) Sexual Dysfunction Pregnancy Category X QT Prolongation Risk Pituitary Apoplexy (rare) PCT Off-Label Risk (unvalidated) WADA ProhibitedSignalsMatrix soonNo community data yetAppears automatically once votes arrive.− -
Vilon
2AA Animal / In VitroIn Plain English: Vilon is a two-amino-acid chain (lysine + glutamic acid) originally isolated from the active fraction of Thymalin, the bovine thymus extract developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. As the simplest known bioregulatory peptide, it exerts outsized effects on the immune system by physically interacting with chromatin — the tightly wound DNA-protein complex inside ageing cells — and loosening regions that had become transcriptionally silent. In ageing immune cells, this allows previously repressed genes to be read again, restoring patterns of T-cell differentiation, cytokine balance, and anti-tumour surveillance that decline with age. Animal studies have documented spontaneous tumour reduction, lifespan extension of 20–40%, and suppression of chemically induced neoplasia. In vitro work in human THP-1 macrophages confirms it reduces TNF-α and IL-6 in response to bacterial challenge. In human skin fibroblast models it raises collagen type I and sirtuin-6 expression. Vilon has no western regulatory approval and is sold internationally as a research compound only.
2D StructureQuick Facts€3.0 Avg / mgFocusCellular Regulation Healthy Aging +1RouteOral SubQEvidenceAnimal / In Vitro ~35–50 peer-reviewed papers (1997–2025), mostly animal/in vitro; no human RCTs, single-group (Khavinson)FlagsNo Western Regulatory Approval No Human Clinical Trial Data Independent Replication Absent No Formal Pharmacokinetic Data Caution in Autoimmune Disease Cancer Context Nuance Mild Injection-Site Reactions ReportedSignalsMatrix soonNo community data yetAppears automatically once votes arrive.− -
Syn-AKE
3AA Limited HumanIn Plain English: Syn-AKE is a lab-made three-amino-acid peptide developed in Basel, Switzerland by Pentapharm AG (now DSM-Firmenich). It copies the key functional region of Waglerin-1, a protein found in the venom of the Temple Viper (Tropidolaemus wagleri) that blocks nerve-to-muscle signalling. Applied topically, it competes with acetylcholine for the receptor slots on the muscle side of the neuromuscular junction — when it wins the slot, the ion channel stays shut, no sodium flows in, and the muscle cell stays relaxed. The result is a temporary softening of dynamic wrinkles (crow's feet, forehead lines, frown lines) — the kind caused by repeated facial movement rather than volume loss. In the primary manufacturer-sponsored human study, a 4% cream applied twice daily for 28 days reduced periorbital wrinkle depth by up to 52%, with measurable smoothing in 80% of the 50 volunteers. The mechanism is reversible and topical: unlike botulinum toxin it does not enter neurons, does not cleave SNARE proteins, and wears off within days of cessation. It is registered as a cosmetic active (INCI: Dipeptide Diaminobutyroyl Benzylamide Diacetate), sold by DSM-Firmenich as a preservative-free glycerin/water solution, used in formulations at 1–4%, and won Switzerland's Technology Award in 2006.
2D StructureQuick Facts€0.18 Avg / mgFocusAesthetic Dermatology Cosmeceutical +1RouteTopicalEvidenceLimited Human ~15 PubMed results for Syn-AKE; human efficacy data manufacturer-commissioned, no independent RCT replicationFlagsTopical Use: Clean Short-Term Safety Profile Manufacturer-Dominated Evidence Base Skin Penetration to Neuromuscular Junction Unproven No Long-Term Safety Data Stability: pH and Heat Sensitive FDA / EU Status: Cosmetic Ingredient Only Not a Neurotoxin in Cosmetic ContextSignalsMatrix soonNo community data yetAppears automatically once votes arrive.− -
Tripeptide-29
3AA Limited HumanIn Plain English: Tripeptide-29 is the most abundant repeating unit in human collagen — the three-amino-acid sequence Glycine-Proline-Hydroxyproline. Applying it topically or ingesting it orally tells fibroblasts that collagen has degraded and new synthesis is needed. At 285 Da it is small enough to penetrate into the upper dermis without a delivery carrier. Manufacturer in-vitro data shows a 400% increase in Type I collagen synthesis at 3% concentration after 48 hours. Human trials on structurally related collagen tripeptide formulations (1 g/day oral, 4–12 weeks) consistently show reduced wrinkle depth, improved skin elasticity, and restored barrier hydration.
2D StructureQuick Facts€0.51 Avg / mgFocusSkin & Aesthetics Soft Tissue SupportRouteTopicalEvidenceLimited Human 400+ PubMed results on Gly-Pro-Hyp / collagen tripeptide; no standalone Tripeptide-29 human RCTFlagsTopical: Clean Safety Record Human Topical RCT Gap In-Vitro Extrapolation Risk Not for Injectable / Systemic Use Formulation pH WindowSignalsMatrix soonNo community data yetAppears automatically once votes arrive.− -
Syn-Coll (Palmitoyl Tripeptide-5)
3AA Limited HumanIn Plain English: Syn-Coll is the trade name for Palmitoyl Tripeptide-5, a synthetic cosmetic active developed by Pentapharm (Switzerland, founded 1948) and now owned by dsm-firmenich following its 2007 acquisition. The molecule is three amino acids — lysine, valine, lysine (Lys-Val-Lys) — attached to a 16-carbon palmitic acid tail. The tail is not decorative: it dramatically improves penetration through the stratum corneum by making the otherwise hydrophilic peptide lipid-compatible, boosting skin residence time and enabling it to reach live dermal fibroblasts. Once there, the Lys-Val-Lys sequence mimics the active domain of thrombospondin-1 (TSP-1), a naturally occurring extracellular matrix glycoprotein. TSP-1 is the body's principal activator of latent TGF-β, and Syn-Coll piggybacks on that pathway: it triggers TGF-β release, which then drives fibroblasts to upregulate collagen type I and type III mRNA transcription. Simultaneously, Syn-Coll inhibits the matrix metalloproteinases MMP-1 and MMP-3 that degrade newly synthesised collagen and suppress pro-inflammatory cytokines that cause capillary permeability and vasodilation. The net result is a build-and-protect action on the extracellular matrix. In a 84-day manufacturer study (n=45), twice-daily application at 1% and 2.5% reduced wrinkle appearance by 7% and 12% respectively. A separate 84-day open-label clinical study (Trookman et al., 2009, n=37) using a multi-ingredient formulation anchored by Palmitoyl Tripeptide-5 showed statistically significant improvement in periocular and perioral fine and coarse wrinkle scores at every timepoint — within minutes, at Month 1, and at Month 3 — with 86% of subjects reporting softening of fine lines and no treatment-related adverse events. In vitro, the peptide at 3 ppm stimulated Type I collagen synthesis by 119% versus untreated controls, and supplier data report roughly 60% greater collagen-building efficacy than Palmitoyl Pentapeptide (Pal-KTTKS). An independent 2025 review (Badilli & Inal, Polymers) confirms the TSP-1 mimicry mechanism. The ingredient is registered under INCI as Palmitoyl Tripeptide-5 (formerly Palmitoyl Tripeptide-3 before a 2010 INCI revision). CAS 623172-56-5 covers the TFA salt used in research; CAS 623172-55-4 covers the free-base cosmetic form. Two-year shelf life when stored at 2–8 °C. No reported sensitisation, toxicity, or endocrine disruption in published literature or CIR review. EWG Skin Deep rates it low hazard across all concern categories.
2D StructureQuick Facts€0.37 Avg / mgFocusCollagen Support Skin & AestheticsRouteTopicalEvidenceLimited Human ~8 relevant papers; no standalone RCT — 1 multi-ingredient open-label trial, rest manufacturer/in vitroFlagsExcellent Topical Safety Record EWG Skin Deep: Low Hazard Cosmetic / Topical Use Only — No Injectable Safety Data All Published Clinical Data from Multi-Ingredient Formulations Negligible Systemic Absorption Expected TFA Salt vs Free Base — Formulation DistinctionSignalsMatrix soonNo community data yetAppears automatically once votes arrive.− -
Thymosin Alpha-1
28AA Extensive HumanIn Plain English: Thymosin Alpha-1 is a naturally occurring 28-amino acid peptide from the thymus gland. It acts as a master regulator of the immune system — teaching immature immune cells to mature, helping fight infections and cancer more precisely, and dialling down dangerous immune overreactions. Used clinically as Zadaxin for decades, primarily for hepatitis B and C.
2D StructureQuick Facts€8.0 Avg / mgFocusAdjunct Oncology Immunity +1RouteIntramuscular SubQEvidenceExtensive Human 858 PubMed papers on thymosin alpha 1; 30+ RCTs across 11,000+ subjectsFlagsInjection Site Reactions Contraindicated in Organ Transplant Active Autoimmune Flare Caution No Dose-Limiting Toxicity US: Compounding Pharmacy OnlySignalsMatrix soonNo community data yetAppears automatically once votes arrive.−
